Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Dénes Csonka"'
Autor:
Dénes Csonka, Vladislav Fishman, Jaya Natarajan, Hans Stieltjes, Danielle Armas, Victor Dishy, Juan Jose Perez Ruixo
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract The COVID‐19 pandemic has forced clinical studies to accommodate imposed limitations. In this study, the bioequivalence part could not be conducted as planned. Thus, the aim was to demonstrate bioequivalence, using an adaptive study design
Externí odkaz:
https://doaj.org/article/31a919ca32f146339e7cacbab7365ba6
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Abstract To compare the pharmacokinetic (PK) properties of the pediatric dispersible tablet formulation of macitentan and the adult film‐coated tablet formulation of macitentan in healthy subjects. A randomized, open‐label, single‐dose, two‐s
Externí odkaz:
https://doaj.org/article/3b790bd2f12d45a28256fdd316cd810a
Autor:
Patricia N. Sidharta, Shirin Bruderer, Susanne Globig, James Carlson, Dénes Csonka, Mariya Antonova, Simon Grill, Armin Schultz
Publikováno v:
British Journal of Clinical Pharmacology
Aims To demonstrate the bioequivalence of macitentan/tadalafil fixed-dose combination (FDC) tablets with single-component tablets of macitentan and tadalafil in healthy subjects. Methods Studies AC-077-101 and AC-077-103 were single-centre, open-labe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32de39e54ed0a875d03df166760e14c2
https://doi.org/10.1111/bcp.14347
https://doi.org/10.1111/bcp.14347
Autor:
Juan Jose Perez-Ruixo, Paolo Magni, Roberta Bartolucci, Dénes Csonka, Anne-Gaëlle Dosne, Italo Poggesi
Publikováno v:
Clinical pharmacokinetics. 60(12)
Macitentan and its active metabolite, aprocitentan, are non-peptide, potent, dual endothelin receptor antagonists. Macitentan is approved for the treatment of pulmonary arterial hypertension in adults, at a dose of 10 mg/day. The objective of this st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::699612687ca30c60be7b3b520c26ea79
https://pubmed.ncbi.nlm.nih.gov/34159557
https://pubmed.ncbi.nlm.nih.gov/34159557
Autor:
Danielle Armas, Vladislav Fishman, Victor Dishy, Juan Jose Perez Ruixo, Jaya Natarajan, Dénes Csonka, Hans Stieltjes
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
The COVID‐19 pandemic has forced clinical studies to accommodate imposed limitations. In this study, the bioequivalence part could not be conducted as planned. Thus, the aim was to demonstrate bioequivalence, using an adaptive study design, of tada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2841b68e0a47d4458789e1fb2e29d094
https://pubmed.ncbi.nlm.nih.gov/34624174
https://pubmed.ncbi.nlm.nih.gov/34624174
Autor:
Radka Stepanova, Armin Schultz, Giancarlo Sabattini, Shirin Bruderer, Dénes Csonka, Juan Jose Perez-Ruixo, Marianne Soergel
Publikováno v:
Clinical Drug Investigation
Background Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important to recognize potential drug–drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab5e853697c0ede27ea0bcb0e1c32b51
https://doi.org/10.1007/s40261-019-00857-7
https://doi.org/10.1007/s40261-019-00857-7
Autor:
Jennifer Lynn Ford, Ahad Sabet, Jaya Natarajan, Hans Stieltjes, Daniel L. Chao, Navin Goyal, Denes Csonka
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 3, Pp n/a-n/a (2024)
Abstract The primary aim was to demonstrate bioequivalence between the 10/20 mg fixed‐dose combination (FDC) of macitentan/tadalafil in a single tablet and the free combination of both drugs, and to evaluate the food effect on the 10/20 mg FDC in h
Externí odkaz:
https://doaj.org/article/9f9481ba906943d08acf091610bbda6a
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
To compare the pharmacokinetic (PK) properties of the pediatric dispersible tablet formulation of macitentan and the adult film‐coated tablet formulation of macitentan in healthy subjects. A randomized, open‐label, single‐dose, two‐sequence,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4226266a311e033e269aa39ac9834d82
http://europepmc.org/articles/PMC7164404
http://europepmc.org/articles/PMC7164404
Publikováno v:
C51. CLOSER TO THE HEART: UPDATE ON APPROVED THERAPIES FOR PAH.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e7e3d95667fafc861cc00423025b7bf
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5065
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5065
Autor:
Michael J. Krowka, Marius M. Hoeper, Emmanuelle Cottreel, Dénes Csonka, O. Sitbon, Colin Church, Jaume Bosch, Nick H. Kim, Nicolas Martin
Publikováno v:
Under pressure: an update in pulmonary vascular disease.
Introduction and objectives Macitentan is an endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension (PAH). The PORTICO trial (NCT02382016) explored the efficacy and safety of macitentan in 85 patients with portop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::179f24c479050f823833418dc865c51f
https://doi.org/10.1136/thorax-2018-212555.175
https://doi.org/10.1136/thorax-2018-212555.175